Product
Corresponding Placebo
Aliases
Placebo
2 clinical trials
1 indication
Indication
HyperlipoproteinemiaClinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in GermanyStatus: Active (not recruiting), Estimated PCD: 2025-06-27
Clinical trial
A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.Status: Recruiting, Estimated PCD: 2028-08-24